Suppr超能文献

丙型肝炎病毒感染的原位肝移植受者中无类固醇诱导与皮质类固醇维持的随机试验:对一年时肝纤维化进展的影响

Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.

作者信息

Kato Tomoaki, Gaynor Jeffrey J, Yoshida Hideo, Montalvano Marzia, Takahashi Hidenori, Pyrsopoulos Nikolaos, Nishida Seigo, Moon Jang, Selvaggi Gennaro, Levi David, Ruiz Phillip, Schiff Eugene, Tzakis Andreas

机构信息

Department of Surgery, University of Miami School of Medicine, Miami, FL, USA.

出版信息

Transplantation. 2007 Oct 15;84(7):829-35. doi: 10.1097/01.tp.0000282914.20578.7b.

Abstract

BACKGROUND

Due to the known high recurrence rate of hepatitis C virus (HCV) among orthotopic liver transplant (OLT) recipients who receive tacrolimus+corticosteroid maintenance, use of steroid-free induction was considered.

METHODS

OLT recipients with HCV were randomized to receive tacrolimus+daclizumab (steroid-free) vs. tacrolimus+corticosteroids during 1999-2001 and then tacrolimus+mycophenolate mofetil (MMF)+daclizumab (steroid-free) vs. tacrolimus+MMF+corticosteroids during 2002-2005. Patients in the steroid-free arm of both periods received no steroids except for treating biopsy-proven rejection. Primary objective was to compare mean fibrosis stage at the 1-year protocol biopsy, between the steroid-free and corticosteroid arms, stratifying by period.

RESULTS

No noticeable differences in mean fibrosis stage between the two treatment arms, either averaging across periods (P=0.99) or during either period (P>0.35) were found. Occurrence of acute rejection during the first year was the only factor associated with a significantly increased fibrosis stage at 1 year (P=0.0003); stage > or =2 was seen in 63% (17 of 27) vs. 19% (8 of 43) of those with vs. without rejection. In addition, MMF use was associated with significantly fewer patients experiencing acute rejection during the first 6 and 12 months posttransplant (P=0.006 and 0.046). Regarding steroid-related side effects, posttransplant diabetes mellitus occurred in 10% vs. 45%, and wound infection in 6% vs. 31% of steroid-free vs. corticosteroid patients (P=0.003 and 0.01).

CONCLUSIONS

OLT recipients with HCV tolerated the steroid-free protocol with fewer side effects; however, its use had no apparent impact on hepatic fibrosis progression. Occurrence of acute rejection was strongly associated with increased hepatic fibrosis at 1 year, and MMF use appears to have significantly reduced the rejection rate.

摘要

背景

由于已知接受他克莫司+皮质类固醇维持治疗的原位肝移植(OLT)受者中丙型肝炎病毒(HCV)复发率较高,因此考虑使用无类固醇诱导治疗。

方法

1999 - 2001年期间,将患有HCV的OLT受者随机分为接受他克莫司+达利珠单抗(无类固醇)组与他克莫司+皮质类固醇组,然后在2002 - 2005年期间,将其随机分为接受他克莫司+霉酚酸酯(MMF)+达利珠单抗(无类固醇)组与他克莫司+MMF+皮质类固醇组。两个时期无类固醇组的患者除治疗经活检证实的排斥反应外不使用类固醇。主要目的是比较无类固醇组和皮质类固醇组在1年方案活检时的平均纤维化分期,并按时期分层。

结果

在两个治疗组之间,无论是跨时期平均(P = 0.99)还是在任何一个时期内(P>0.35),均未发现平均纤维化分期有明显差异。第一年急性排斥反应的发生是与1年时纤维化分期显著增加相关的唯一因素(P = 0.0003);有排斥反应者中63%(27例中的17例)出现分期≥2期,而无排斥反应者中为19%(43例中的8例)。此外,使用MMF与移植后前6个月和12个月期间发生急性排斥反应的患者明显减少相关(P = 0.006和0.046)。关于类固醇相关的副作用,无类固醇组与皮质类固醇组患者移植后糖尿病的发生率分别为10%和45%,伤口感染发生率分别为6%和31%(P = 0.003和0.01)。

结论

患有HCV的OLT受者对无类固醇方案耐受性良好,副作用较少;然而,其使用对肝纤维化进展没有明显影响。急性排斥反应的发生与1年时肝纤维化增加密切相关,使用MMF似乎显著降低了排斥反应率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验